Core Viewpoint - MediciNova, Inc. has announced a Standby Equity Purchase Agreement (SEPA) allowing the company to raise up to $30 million in common stock over 36 months to support its R&D initiatives and general corporate activities [1][2][3]. Group 1: SEPA Details - The SEPA allows MediciNova to sell its common stock at a price equal to 97% of the market price, with the right to sell up to 100% of the daily trading volume during the five days prior to the transaction [2][4]. - The proceeds from the SEPA will be utilized to advance R&D programs and for general corporate purposes [2][3]. Group 2: Company Strategy and Focus - MediciNova is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, primarily targeting the U.S. market [5]. - The company is concentrating its development efforts on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic and metabolic disorders [5].